ACAD FY 2022 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$517M+6.8% YoY

Gross Profit

$507M98.0% margin

Operating Income

-$224M-43.2% margin

Net Income

-$216M-41.8% margin

EPS (Diluted)

$-1.34

Cash Flow

Operating Cash Flow

-$114M

Free Cash Flow

-$114M

Stock-Based Comp.

$68M

Balance Sheet

Total Assets

$588M

Total Liabilities

$187M

Stockholders' Equity

$400M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$517M	$484M	+6.8%
Gross Profit	$507M	$465M	+9.0%
Operating Income	-$224M	-$170M	-31.2%
Net Income	-$216M	-$168M	-28.7%